Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Beauty Health (SKIN) Interest & Investment Income (2020 - 2025)

Beauty Health (SKIN) has disclosed Interest & Investment Income for 6 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income fell 74.24% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.7 million, a 53.6% decrease, with the full-year FY2024 number at $16.6 million, down 28.18% from a year prior.
  • Interest & Investment Income was $1.3 million for Q3 2025 at Beauty Health, down from $3.2 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $19.2 million in Q4 2022 to a low of -$2.1 million in Q2 2021.
  • A 5-year average of $3.7 million and a median of $3.0 million in 2025 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: plummeted 103.52% in 2022, then soared 143933.33% in 2023.
  • Beauty Health's Interest & Investment Income stood at $2.5 million in 2021, then surged by 653.66% to $19.2 million in 2022, then crashed by 66.66% to $6.4 million in 2023, then crashed by 65.29% to $2.2 million in 2024, then crashed by 43.37% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for SKIN's Interest & Investment Income are $1.3 million (Q3 2025), $3.2 million (Q2 2025), and $3.0 million (Q1 2025).